As the COVID-19 pandemic evolves, we are continuing to take steps to ensure the health and safety of our workforce and the continuity of our influenza vaccine operations across the Seqirus global network.

• We continue to follow the latest advice from relevant authorities to guide the implementation of safety measures for our staff, including hygiene and cleaning protocols, remote working arrangements, and travel and group meeting bans.
• We have enacted our business continuity plans across our global network to minimise disruption to the manufacture and on-time supply of our influenza vaccines and are closely tracking any potential impacts to our operations.
• We have ongoing clinical trials evaluating new influenza vaccine approaches. and remain in close contact with the researchers involved in this important work, discussing the best ways to manage subject visits and follow-up appointments.
• We are providing technical expertise and our well-established MF59® adjuvant technology to the University of Queensland in Australia to help fast-track the development of their CEPI-funded n-COV19 vaccine candidate.

Seqirus is part of CSL Limited (ASX:CSL).  See the full CSL Group statement here.